Abstract:Objective:To explore the efficacy and safety of intermittent infusion of ilaprazole sodium and high-dose continuous infusion of esomeprazole sodium in preventing rebleeding in patients with peptic ulcer bleeding after successful endoscopic hemostasis.Methods:This is a multi-center, interval randomized, double-blind, double-dummy, parallel controlled study. From March 3rd to June 15th, 2021, 151 patients with high risk of peptic ulcer bleeding and successfully underwent endoscopic hemostasis from 33 hospitals including the First Affiliated Hospital of Zhejiang University School of Medicine were enrolled. Patients were interval randomly divided into the trial group (74 cases) and the control group (77 cases). Patients in the trial group received intermittent intravenous infusion of ilaprazole sodium once daily (20 mg administered as a 60 min intravenous infusion on day 1, and 10 mg administered as a 30 min intravenous infusion on day 2 and 3); patients in the control group received continuous intravenous infusion of esomeprazole sodium for 72 h (esomeprazole sodium 80 mg at first dose in half an hour, and 8 mg per hour continuous intravenous infusion for 71.5 h). After intravenous infusion treatment, patients of both groups were given oral ilaprazole enteric-coated tablets, 10 mg each time, once a day for 4 d. The rebleeding rate after 72 h and within 7 d after treatment and the proportion of patients who received endoscopic retreatment or surgery due to rebleeding within 72 h after treatment were analysised based on the full analysis set (72 cases in the trial group and 75 cases in the control group); and the incidence rate of adverse reactions was observed in the two groups based on the safety analysis set (74 cases in the trial group and 76 cases in the control group). Chi-square test or Fisher exact probability test was used for statistical analysis.Results:There was no rebleeding case in the trial group within 72 h and 1 case of rebleeding within 7 d (1.39%, 1/72). In the control group, there was 1 case of rebleeding (1.33%, 1/75) within 72 h and 4 cases of rebleeding (5.33%, 4/75) within 7 d. There was no significant difference in rebleeding rate either after 72 h or within 7 d after treatment between the two groups (both P>0.05). Within 72 h of treatment, no patients in both groups needed endoscopic or surgical retreatment due to rebleeding. Adverse reactions occurred in 5 cases (6.8%, 5/74) and 6 cases (7.9%, 6/76) in the trial group and control group, respectively, which recovered spontaneously without treatment. No serious adverse reactions occurred in both groups. Conclusion:In patients with high-risk peptic ulcer bleeding with successful endoscopic hemostasis, intermittent intravenous infusion of ilaprazole sodium has similar efficacy and safety as continuous high-dose intravenous infusion of esomeprazole sodium, but the dosage of intermitten regimen is less, the administration is more convenient, and it is worthy of clinical promotion.

The Efficacy of Esomeprazole in Preventing Stress Ulcer in the Mechanical Ventilation Patients

Effect of Omeprazole in treating peptic ulcers of children

The Symptomatic Improvement and Safety of Rabeprazole on Peptic Ulcer

Efficacy comparison of pantoprazole and famotidine in prevention of stress ulcer after hepatobiliary surgery

Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation

The controlled study of efficacy and safety of infusion of ilaprazole sodium versus esomeprazole sodium in prevention of peptic ulcer rebleeding

Logistic Regression Analysis on Risk Factors of Mechanical Ventilation Complicated with Stress Ulcer

Analysis of the Cost-effectiveness of 2 Kinds Regimens in the Treatment of Brain Trauma and Cerebral Hem-orrhage Complicated with Upper Gastrointestinal Hemorrhage

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

The Prevention of Upper Gastrointestinal Bleeding in Seriously Ill Chinese Patients: A Randomised, Double-Blind Study Evaluating Esomeprazole Vs Cimetidine

EFFICACY OF INTRAVENOUS ADMINISTRATION OF OMEPRAZOLEIN THE TREATMENT OF UPPER GASTROINTESTINAL HEMORRHAGE CAUSED BY PEPTIC ULCER AND ACUTE GASTRIC MUCOSAL LESION

A randomized controlled study of roxatidine in the prevention of stress related mucosal disease

The Effect of Low-Dose Omeprazole on 24-Hour Intragastric Ph in Healthy Human Subjects

Effect of omeprazole in treatment of peptic ulcer bleeding

Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine

Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

Clinical Effect of Esomeprazole Combined with Trimebutine Maleate Tablets for Treatment of Erosive Esophagitis

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

Clinical comparison of rabeprazole and omeprazole in the treatment of reflux esophagitis

Clinical efficacy of omeprazole combined mosapride in treating reflux esophagitis